BPO-27 racemate

BPO-27 racemate is a potent CFTR inhibitor with an IC 50 of 8 nM.

In Vitro

The benzopyrimido-pyrrolo-oxazinedione BPO-27 is an analogue of PPQ-102, which inhibits CFTR with an IC 50 of 8 nM. The R enantiomer of BPO-27 inhibits CFTR chloride conductance with an IC 50 of 4 nM, while S enantiomer is inactive. In vitro metabolic stability in hepatic microsomes shows both enantiomers as stable, with less than 5% metabolism in 4 h. (R)-BPO-27 binds near the canonical ATP binding site. Whole-cell patch-clamp studies shows linear CFTR currents with a voltage-independent (R)-BPO-27 block mechanism. At a concentration of (R)-BPO-27 that inhibits CFTR chloride current by 50%, the EC 50 for ATP activation of CFTR increases from 0.27 to 1.77 mM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Following bolus interperitoneal administration in mice, serum (R)-1 decays with t 1/2 ≈ 1.6 h and gives sustained therapeutic concentrations in kidney . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay

Whole-cell recordings are done on CFTR-expressing CHO-K1 cells. After establishing the whole-cell configuration, BPO-27 is added for 5 minutes, and then CFTR is activated by the addition of forskolin (10 μM) in the continued presence of BPO-27 (0.5 or 1 μM). Whole-cell currents are elicited by applying hyperpolarizing and depolarizing voltage pulses from a holding potential of 0 mV to potentials between +80 and −80 mV in steps of 20 mV. Recordings are made at room temperature using an Axopatch-200B. Currents are digitized with a Digidata 1440A converter and filtered at 5 kHz. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:IC50: 8 nM